LD50=~900 mg/kg (Orally in rats); LD50=90 mg/kg (Orally in women); Signs of overdose include motor unrest, muscular twitching and rigidity, tremor, ataxia, convulsions, hyperpyrexia, vertigo, mydriasis, vomiting, cyanosis, hypotension, shock, tachycardia, cardiac arrhythmias, impaired cardiac conduction, respiratory depression, and disturbances of consciousness up to deep coma.
Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Deferasirox | The serum concentration of Maprotiline can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Maprotiline can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Maprotiline can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Maprotiline can be decreased when it is combined with Teriflunomide. |
| Buprenorphine | Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline. |
| Hydrocodone | Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Maprotiline can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Maprotiline may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline. |
| Orphenadrine | Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Maprotiline. |
| Pramipexole | Maprotiline may increase the sedative activities of Pramipexole. |
| Ropinirole | Maprotiline may increase the sedative activities of Ropinirole. |
| Rotigotine | Maprotiline may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Maprotiline. |
| Sodium oxybate | Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline. |
| Thalidomide | Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Aclidinium | The risk or severity of adverse effects can be increased when Maprotiline is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Maprotiline. |
| Mirabegron | The risk or severity of urinary retention can be increased when Maprotiline is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Maprotiline is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Maprotiline. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Maprotiline. |
| Tiotropium | The risk or severity of adverse effects can be increased when Maprotiline is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Maprotiline is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Maprotiline is combined with Umeclidinium. |
| Benzylpenicilloyl polylysine | Maprotiline may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Maprotiline. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Maprotiline. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Maprotiline. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Maprotiline. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Maprotiline. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Maprotiline is combined with Glycopyrronium. |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Maprotiline. |
| Pargyline | The risk or severity of adverse effects can be increased when Pargyline is combined with Maprotiline. |
| Hydracarbazine | The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Maprotiline. |
| Benmoxin | The risk or severity of adverse effects can be increased when Benmoxin is combined with Maprotiline. |
| Mebanazine | The risk or severity of adverse effects can be increased when Mebanazine is combined with Maprotiline. |
| Octamoxin | The risk or severity of adverse effects can be increased when Octamoxin is combined with Maprotiline. |
| Pheniprazine | The risk or severity of adverse effects can be increased when Pheniprazine is combined with Maprotiline. |
| Phenoxypropazine | The risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Maprotiline. |
| Pivhydrazine | The risk or severity of adverse effects can be increased when Pivhydrazine is combined with Maprotiline. |
| Safrazine | The risk or severity of adverse effects can be increased when Safrazine is combined with Maprotiline. |
| Caroxazone | The risk or severity of adverse effects can be increased when Caroxazone is combined with Maprotiline. |
| Furazolidone | The risk or severity of adverse effects can be increased when Furazolidone is combined with Maprotiline. |
| 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Maprotiline. |
| Harmaline | The risk or severity of adverse effects can be increased when Harmaline is combined with Maprotiline. |
| Brofaromine | The risk or severity of adverse effects can be increased when Brofaromine is combined with Maprotiline. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Maprotiline. |
| Safinamide | The risk or severity of adverse effects can be increased when Safinamide is combined with Maprotiline. |
| Procaine | The risk or severity of adverse effects can be increased when Procaine is combined with Maprotiline. |
| Phenelzine | The risk or severity of adverse effects can be increased when Phenelzine is combined with Maprotiline. |
| Minaprine | The risk or severity of adverse effects can be increased when Minaprine is combined with Maprotiline. |
| Selegiline | The risk or severity of adverse effects can be increased when Selegiline is combined with Maprotiline. |
| Moclobemide | The risk or severity of adverse effects can be increased when Moclobemide is combined with Maprotiline. |
| Isocarboxazid | The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Maprotiline. |
| Clorgiline | The risk or severity of adverse effects can be increased when Clorgiline is combined with Maprotiline. |
| Iproniazid | The risk or severity of adverse effects can be increased when Iproniazid is combined with Maprotiline. |
| Nialamide | The risk or severity of adverse effects can be increased when Nialamide is combined with Maprotiline. |
| Pirlindole | The risk or severity of adverse effects can be increased when Pirlindole is combined with Maprotiline. |
| Toloxatone | The risk or severity of adverse effects can be increased when Toloxatone is combined with Maprotiline. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Maprotiline. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Maprotiline is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Maprotiline is combined with Phenindione. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Maprotiline is combined with Phenprocoumon. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Maprotiline is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Maprotiline is combined with Coumarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Maprotiline is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Maprotiline is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Maprotiline is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Maprotiline is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Maprotiline is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Maprotiline is combined with (S)-Warfarin. |
| Tedizolid phosphate | The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Maprotiline. |
| Abiraterone | The serum concentration of Maprotiline can be increased when it is combined with Abiraterone. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type A. |
| Glucagon | Maprotiline may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Maprotiline may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type B. |
| Mirtazapine | Maprotiline may increase the serotonergic activities of Mirtazapine. |
| Eluxadoline | The risk or severity of constipation can be increased when Maprotiline is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Maprotiline is combined with Ramosetron. |
| Cyproterone acetate | The metabolism of Maprotiline can be increased when combined with Cyproterone acetate. |
| Ethanol | Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline. |
| Zimelidine | The risk or severity of adverse effects can be increased when Maprotiline is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Maprotiline is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Maprotiline is combined with Seproxetine. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Citalopram. |
| Sertraline | The risk or severity of adverse effects can be increased when Maprotiline is combined with Sertraline. |